SCHEMBL12726993

SCHEMBL12726993

NNC(=O)c1sc2cc(F)ccc2c1Cl

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCKDK O14874 1/20 0.68
RAB9A P51151 6/20 0.67
LMNA P02545 4/20 0.67
MAPT P10636 3/20 0.67
GAA P10253 2/20 0.67
KDM4E B2RXH2 2/20 0.67
ALDH1A1 P00352 2/20 0.67
SENP1 Q9P0U3 1/20 0.67
OGG1 O15527 2/20 0.64
SMN1; SMN2 Q16637 3/20 0.61
HPGD P15428 1/20 0.61
NPC1 O15118 4/20 0.60
TSHR P16473 1/20 0.60
TP53 P04637 1/20 0.60
TLR3 O15455 1/20 0.60
PTGS1 P23219 1/20 0.56
MAOB P27338 1/20 0.56
CASP3 P42574 1/20 0.56
GPER1 Q99527 1/20 0.56
MEN1 O00255 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8278999 0.85 BCKDK (0.68) BCKDKRAB9ALMNAMAPTGAA
SCHEMBL2279755 0.81 BCKDK (0.77) BCKDKRAB9ALMNAMAPTKDM4E
SCHEMBL594468 0.81 BCKDK (1.00) BCKDKRAB9ALMNAMAPTKDM4E
SCHEMBL2610278 0.80 BCKDK (0.74) BCKDKRAB9ALMNAMAPTGAA
SCHEMBL8414188 0.80 MAPT (1.00) RAB9ALMNAMAPTGAAKDM4E
SCHEMBL693146 0.79 BCKDK (0.68) BCKDKRAB9ALMNAMAPTGAA
SCHEMBL6477287 0.78 OGG1 (1.00) RAB9ALMNAMAPTGAAKDM4E
SCHEMBL13659611 0.77 BCKDK (0.68) BCKDKRAB9ALMNAMAPTKDM4E
SCHEMBL11301956 0.76 TLR3 (1.00) BCKDKRAB9ALMNAMAPTALDH1A1
SCHEMBL11951242 0.76 TLR3 (1.00) BCKDKRAB9ALMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 BCKDK 2580/4885RAB9A 2696/4885LMNA 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.